This is critically important since numerous JAK2 inhibitors are currently in active clinical development for hematopoietic proliferative disorders and malignancies.47,48 Future work should examine the potential of JAK2 inhibitors as adjuvant therapy for reducing BM in NSCLC patients. Here, JAK2 is linked to non-small cell lung carcinoma.